Supplementary Figure S7 Anti-tumor efficacy of ATOR-4066 at different doses in hCD40tgxC57BL/6 mice. MC38-CEA bearing mice were treated i.p. with ATOR-4066 at multiple doses or vehicle on day 6, 10 and 13 and tumor volume was measured and survival monitored. Group size n = 10 to 20, pooled data from two experiments. Each line represents tumor volume of individual mice.
Supplementary Figure S6 Anti-tumor efficacy of titration of ATOR-4066 dose in MC38-CEA bearing mice. F1 (hCD40tgxC57BL/6) mice were treated i.p. with vehicle, or 0.5 mg/kg (10 ug/mouse), 1 mg/kg (20 ug/mouse), 2 mg/kg (40 ug/mouse), 3 mg/kg (60 ug/mouse), 4 mg/kg (80 ug/mouse), 6.25 mg/kg (125 ug/mouse) or 8.35 mg/kg (167 ug/mouse) of ATOR-4066 on days 6, 10 and 13. Tumors were measured twice a week. Each line represents tumor volume of individual mice. Size n = 10 to 29/group.
Despite recent progress within the field of immuno-oncology, immune suppression in the tumor microenvironment, defective antigen presentation, and low levels of tumor-specific T cells are key limitations of current cancer immunotherapies. CD40-targeting immunotherapies hold promise for addressing these limitations across solid tumors. In this study, we describe ATOR-4066, a bispecific antibody that targets CD40 and CEACAM5, developed using the Neo-X-Prime platform. ATOR-4066 showed potent CEACAM5-dependent activation in vitro, with an ability to activate intratumoral immune cells from patient-derived material. In vivo, ATOR-4066 induced superior antitumor activity compared with a CD40 mAb in MC38–carcinoembryonic antigen tumors and cured mice with well-established tumors with heterogeneous CEACAM5 expression. Using RNA sequencing, flow cytometry, and cytokine analysis, we showed that ATOR-4066 promoted immune cell trafficking to tumors and activated both myeloid cells and T cells within the tumor microenvironment, with limited immune activation in the periphery. ATOR-4066 initially induced a T cell–independent antitumor response, yet we found that a functional T-cell response was critical for long-term tumor control and immunity directed to tumor antigens other than CEACAM5. Finally, we demonstrated that ATOR-4066 synergized with PD-1 blockade in vitro. In conclusion, these data provide mechanistic evidence for the proposed mode of action and support further development of ATOR-4066 in CEACAM5-expressing cancers.
Supplementary Figure S16. The importance of T cells during treatment was evaluated using aCD4 and aCD8 depleting antibodies in F1 hCD40tgxC57BL/6 mice, inoculated with MC38-CEA and treated with ATOR-4066 or vehicle 6, 10 and 13 days after tumor inoculation.
Supplementary Figure S5 B cells were enriched from PBMCs isolated from leucocyte concentrates obtained from healthy donors using B Cell Isolation Kit II, human (Miltenyi, 130-091-151). 50,000 B cells were incubated with IL-4 (10 ng/mL) in 96-well plates together with CHO-CEACAM5 cells (60,000 cells/well), CHO-WT cells (60,000 cells/well), soluble CEACAM5 (s-CEA) or combination of CHO-CEACAM5 and s-CEA, with or without ATOR-4066 (1 nM). After 48 hours, the cells were stained for viability and expression of CD45, CD19 and CD86 and analyzed by flow cytometry. The figure shows percentage of B cells expressing CD86. ATOR-4066 induce activation of B cells in co-cultures of CHO-CEACAM5 cells, but not CHO-WT cells, and this activation is not reduced by addition of s-CEA. Moreover, ATOR-4066 in the sole presence of s-CEA does not activate B cells.
Supplementary Figure S10. Representative images of immunohistochemistry analysis (performed by Truly Labs, Lund, Sweden). Antibody accumulation in MC38-CEA tumors as quantified in figure 2. Equimolar doses of mAb and bsAb (100 µg and 167 µg, respectively). Treatment day 10 and 13 after inoculation, analysis at day 14.